MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Citius Pharmaceuticals Inc

Healthcare US CTXR


Last update at 2024-07-11T14:49:00Z

Day Range


52 Week Range



  • Previous Close 0.75
  • Market Cap115.83M
  • Volume1697453
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-39.10550M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.23


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Income before tax -33.06465M -23.05443M -17.54809M -15.56214M -12.53664M
Minority interest - - - - -
Net income -33.64065M -23.12519M -17.67396M -15.57859M -12.53664M
Selling general administrative 15.66M 11.29M 8.90M 7.00M 7.23M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.18M 0.16M 0.15M 0.00089M 0.00175M
Ebit -33.31605M -23.53189M -17.71069M -15.59836M -12.52080M
Ebitda -32.88497M -23.04528M -17.38005M -15.54481M -12.51905M
Depreciation and amortization 0.43M 0.49M 0.33M 0.05M 0.00175M
Non operating income net other - 0.49M 0.18M 0.05M 1.27M
Operating income -33.31605M -23.53189M -17.71069M -15.59836M -13.78914M
Other operating expenses 33.32M 23.53M 17.71M 15.60M 13.79M
Interest expense 0.25M 0.01M 0.02M 0.02M 0.02M
Tax provision 0.58M - 0.00000M 0.00000M 0.00000M
Interest income 0.25M 0.26M 0.07M 0.05M 0.00000M
Net interest income 0.25M 0.25M 0.05M 0.04M -0.01584M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.58M 0.07M 0.13M 0.02M 1.28M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 33.32M 23.53M 17.71M 15.60M 13.79M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.25M 0.48M 0.16M 0.04M 1.27M
Discontinued operations - - - - -
Net income from continuing ops -33.64065M -23.05443M -17.54809M -15.56214M -12.53664M
Net income applicable to common shares -33.64065M -24.50531M -17.54809M -15.56214M -12.53664M
Preferred stock and other adjustments - 1.45M - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 103.61M 114.00M 142.43M 43.77M 28.99M
Intangible assets 59.40M 59.40M 59.40M 19.40M 19.40M
Earning assets - - - - -
Other current assets 7.89M 2.85M 2.74M 0.12M 0.05M
Total liab 12.18M 10.57M 9.65M 10.10M 4.61M
Total stockholder equity 90.83M 102.83M 132.18M 33.67M 24.38M
Deferred long term liab - 5.56M 4.99M 4.99M -
Other current liab 2.63M 3.17M 2.53M 1.91M 1.72M
Common stock 0.16M 0.15M 0.15M 0.06M 0.03M
Capital stock 0.16M 0.15M 0.15M 0.06M 0.03M
Retained earnings -162.23138M -129.68847M -96.04782M -70.59387M -55.81998M
Other liab - 5.56M 4.99M 4.99M 4.99M
Good will 9.35M 9.35M 9.35M 9.35M 1.59M
Other assets - 0.04M 0.04M 0.06M 0.06M
Cash 26.48M 41.71M 70.07M 13.86M 7.89M
Cash and equivalents - - - - -
Total current liabilities 5.78M 4.53M 3.98M 4.10M 4.61M
Current deferred revenue - - - - -
Net debt -25.99968M -41.03346M -69.21747M -12.50773M -7.72083M
Short term debt 0.22M 0.20M 0.18M 0.33M 0.17M
Short long term debt - - - 0.17M 0.17M
Short long term debt total 0.48M 0.68M 0.86M 1.35M 0.17M
Other stockholder equity 252.90M 232.37M 228.08M 104.21M 80.17M
Property plant equipment - 0.00410M 0.00702M 0.00158M 0.00059M
Total current assets 34.37M 44.56M 72.81M 13.98M 7.94M
Long term investments - - - - -
Net tangible assets - 102.83M 132.18M 33.67M -1.59392M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - 0.16M -
Inventory - - - - -
Accounts payable 2.93M 1.17M 1.28M 1.86M 2.71M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 0.60M 0.60M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - 0.15M 0.15M 0.06M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -129.68847M -96.04782M -70.59387M -55.81998M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 44.95M 39.97M 0.04M 0.06M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 69.24M 69.44M 69.61M 29.79M 21.04M
Capital lease obligations 0.48M 0.68M 0.86M 1.01M -
Long term debt total - - - 0.16M -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Investments 0.00000M -40.00694M -0.00183M 0.00000M 0.00000M
Change to liabilities 0.53M 0.13M -0.68526M 1.41M 0.97M
Total cashflows from investing activities - -40.00694M -0.00183M -0.00183M -0.00183M
Net borrowings - -0.17247M 0.16M 0.16M 0.16M
Total cash from financing activities 0.00000M 120.47M 22.90M 11.15M 17.30M
Change to operating activities 0.35M -2.13813M -0.00966M 0.24M 0.36M
Net income -33.64065M -23.05443M -17.54809M -15.56214M -12.53664M
Change in cash -28.36126M 56.21M 5.97M -1.29020M 5.98M
Begin period cash flow 70.07M 13.86M 7.89M 9.18M 3.20M
End period cash flow 41.71M 70.07M 13.86M 7.89M 9.18M
Total cash from operating activities -28.36126M -24.25041M -16.93066M -12.43775M -11.31814M
Issuance of capital stock 0.00000M 89.43M 15.58M 11.12M 16.17M
Depreciation 0.18M 0.16M 0.15M 0.00089M 0.00175M
Other cashflows from investing activities - -40.00000M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.82M -0.81834M
Sale purchase of stock - 120.64M 7.16M 0.02M 17.30M
Other cashflows from financing activities - 31.21M 7.32M 0.02M 1.13M
Change to netincome 4.48M 1.29M 0.80M 0.72M 0.71M
Capital expenditures 0.00000M 40.01M 0.00183M 0.00183M 0.00183M
Change receivables - -0.08800M 0.02M 0.83M -0.80270M
Cash flows other operating 0.27M -2.52776M 0.48M 0.17M 0.54M
Exchange rate changes - - - - -
Cash and cash equivalents changes -28.36126M 56.21M 5.97M -1.29020M 5.98M
Change in working capital 0.24M -2.71727M -0.86697M 2.20M 0.51M
Stock based compensation 3.91M 1.45M 0.80M 0.72M 0.78M
Other non cash items 0.38M 0.07M 0.53M 0.21M 0.38M
Free cash flow -28.36126M -64.25735M -16.93249M -12.43775M -11.31814M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
Citius Pharmaceuticals Inc
0.0063 0.84% 0.75 - 1.29 - 1.49 -2.7425
Novo Nordisk A/S
-1.54 1.08% 141.20 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
-0.09 0.06% 141.25 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
-1.14 0.23% 490.48 29.67 24.33 10.38 5.83 9.33 20.00
Regeneron Pharmaceuticals Inc
10.39 0.97% 1081.52 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News


Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals Inc

11 Commerce Drive, Cranford, NJ, United States, 07016

Key Executives

Name Title Year Born
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Sec. 1945
Mr. Myron Z. Holubiak Co-Founder & Exec. Vice Chairman 1947
Mr. Jaime Bartushak Chief Bus. Officer, CFO & Chief Accounting Officer 1968
Dr. Myron S. Czuczman M.D. Exec. VP & Chief Medical Officer 1960
Mr. Gary F. Talarico Exec. VP of Operations 1955
Ms. Ilanit Allen VP of Investor Relations & Corp. Communications NA
Dr. Alan Lader Ph.D. Sr. VP & Head of Clinical Operations and Quality Assurance NA
Mr. Dhananjay G. Wadekar Sr. VP of Bus. Strategy 1954
Mr. Kelly Creighton Ph.D. Exec. VP of Chemistry, Manufacturing & Controls NA
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Secretary 1945

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.